https://repositorio.ufba.br/handle/ri/5029
Tipo: | Artigo de Periódico |
Título: | Efficacy and Safety of Efavirenz in HIV Patients on Rifampin for Tuberculosis |
Título(s) alternativo(s): | The Brazilian Journal of Infectious Diseases |
Autor(es): | Sampaio, Diana Brasil Pedral Alves, Carmosina R. Martins Netto, Eduardo Brites, Carlos Badaró, Roberto José da Silva Oliveira, Adriano S. |
Autor(es): | Sampaio, Diana Brasil Pedral Alves, Carmosina R. Martins Netto, Eduardo Brites, Carlos Badaró, Roberto José da Silva Oliveira, Adriano S. |
Abstract: | Forty-nine AIDS patients, most of who were antiretroviral therapy (ARV) naïve, with active tuberculosis, were treated with Rifampin 600mg, Isoniazid 400mg and Pirazinamide 2g daily. They also received ARV, consisting of Efavirenz (600mg/day) plus 2 NRTIs. All patients were prospectively followed for at least 24 months. Baselines were: male/female ratio 2:1, mean age 34.7 ± 9.4 yrs; weight 51 ± 9.0 kg, viral load 5.6 ± 0.6 logs, CD4 cell count 101 ± 128 cells/ mm3. Follow up mean values of data logs of VL and CD4 + cell /mm3 counts were: VL 1.7 and CD4 + 265; VL 1.3 and CD4 + 251; VL 1.4 and CD4 + 326 at 6, 12 and 24 months, respectively. Weight gain changes were: 5 ± 9.9 ± 12 and 21 ± 16 kg respectively at 6, 12 and 24 months. A non-concomitant ARV regimen was introduced at least three weeks after TB treatment initiation. Severe adverse reactions included rash (two), toxic hepatitis (six), Immune Reconstitution Syndrome (seven), and four deaths. We conclude that Efavirenz at a daily dose of 600 mg is sufficient and safe to treat HIV/TB patients using a Rifampin containing regimen. |
Palavras-chave: | Tuberculosis HIV/AIDS drug interaction Rifampin Efavirenz antiretroviral therapy |
URI: | http://www.repositorio.ufba.br/ri/handle/ri/5029 |
Data do documento: | 2004 |
Aparece nas coleções: | Artigo Publicado em Periódico Nacional (ISC) |
Arquivo | Descrição | Tamanho | Formato | |
---|---|---|---|---|
21618.pdf | 80,46 kB | Adobe PDF | Visualizar/Abrir |
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.